Share this

References:

  1. Food and Drug Administration. Center for Biologics Evaluation and Research (CBER). CBER clinical review of studies submitted in support of licensure
    of ProQuad. https://www.fda.gov/media/165978/download. Accessed July 2026.
  2. World Health Organization. Rubella reported cases and incidence. Immunization Data. Accessed July, 2026 https://immunizationdata.who.int/-
    global/wiise-detail-page/rubella-reported-cases-and-incidence?CODE=Global&YEAR=
  3. Lanzieri T, Haber P, Icenogle JP, Patel M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book).14th edition. Chapter 20: Rubella.
    Centers for Disease Control and Prevention. April 25, 2024. Accessed July, 2026. https://www.cdc.gov/pinkbook/hcp/table-of-contents/
    chapter-20-rubella.html
  4. World Health Organization.Congenital Rubella Syndrome (CRS) reported cases and incidence. Accessed July, 2026.https://immunizationdata.who.int/-
    global/wiise-detail-page/congenital-rubella-syndrome-(crs)-reported-cases-and-incidenceby-year
  5. Babigumira JB et al. BMC Public Health. 2013;13:406.
  6. Lebo E, Vynnycky E, Alexander Jr. JP, et al. Estimated current and future congenital rubella syndrome incidence with and without rubella vaccine introduction
    — 19 countries, 2019–2055. MMWR Morb Mortal Wkly Rep.2025;74(18):305– 311. doi:10.15585/mmwr.mm7418a3.

AE-QDX-00012 | Exp: 25 July 2028